Moxydar (Aluminium Oxide, Hydrated, Aluminium Phosphate, Hydrated, Guar, Magnesium Hydroxide)

The active ingredients—aluminium oxide, aluminium phosphate, magnesium hydroxide and guar—react chemically with hydrochloric acid in the stomach. This reaction forms neutral salts and water, raising the gastric pH and reducing acidity. Guar serves as a suspending agent, ensuring even distribution of the antacid particles.

The appropriate dose of Moxydar is determined by a qualified healthcare professional based on the individual’s age, severity of symptoms and overall health status. Patients should follow the prescriber’s instructions and not exceed the recommended amount on the product label.

Safety data for Moxydar in pregnancy and lactation are limited. Women who are pregnant, planning to become pregnant, or breastfeeding should consult their physician before using the product to weigh potential benefits against any possible risks.

To place an order, submit an enquiry on the Moxydar product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Moxydar combines aluminium and magnesium salts, offering a balanced approach that can minimise the constipation associated with aluminium‑only products and the diarrhoea linked to magnesium‑only formulations. This dual‑action profile often provides more comfortable symptom control compared with single‑ingredient antacids.

Moxydar should be stored at ambient temperature, preferably below 25 °C, in its original packaging to protect it from moisture and light. Keep the container tightly closed and out of reach of children.

Moxydar is taken orally, usually with a glass of water. It can be taken with or without food, but patients should follow the dosing instructions provided by their healthcare professional or the product label.

Serious risks, although rare, include hypermagnesemia, metabolic alkalosis and severe allergic reactions such as rash, swelling or anaphylaxis. Patients experiencing any of these symptoms should seek immediate medical attention.

Moxydar should be avoided by individuals with known hypersensitivity to any of its components, those with severe renal impairment, and patients who are already receiving high doses of aluminium or magnesium from other sources. Consultation with a healthcare provider is essential before use.